Nationwide Fund Advisors lifted its stake in shares of Mednax, Inc (NYSE:MD) by 9.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 467,917 shares of the company’s stock after buying an additional 39,490 shares during the quarter. Nationwide Fund Advisors owned 0.50% of Mednax worth $28,248,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in MD. BlackRock Inc. raised its holdings in shares of Mednax by 5,766.0% during the 1st quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock valued at $570,952,000 after buying an additional 8,089,052 shares during the period. Thompson Siegel & Walmsley LLC raised its holdings in shares of Mednax by 95.9% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after buying an additional 1,062,584 shares during the period. Schroder Investment Management Group raised its holdings in shares of Mednax by 144.1% during the 1st quarter. Schroder Investment Management Group now owns 1,734,697 shares of the company’s stock valued at $120,458,000 after buying an additional 1,024,048 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Mednax by 62.9% during the 1st quarter. Victory Capital Management Inc. now owns 1,977,791 shares of the company’s stock valued at $137,219,000 after buying an additional 763,633 shares during the period. Finally, Clearbridge Investments LLC raised its holdings in shares of Mednax by 33.1% during the 1st quarter. Clearbridge Investments LLC now owns 2,048,277 shares of the company’s stock valued at $142,109,000 after buying an additional 508,863 shares during the period.

Several brokerages recently commented on MD. Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. Stifel Nicolaus dropped their target price on Mednax from $65.00 to $58.00 and set a “hold” rating on the stock in a report on Thursday, May 25th. Mizuho dropped their target price on Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a report on Tuesday, May 30th. BidaskClub upgraded Mednax from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, Jefferies Group LLC set a $46.00 target price on Mednax and gave the company a “hold” rating in a report on Sunday, July 30th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $59.88.

In related news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Nationwide Fund Advisors Has $28.25 Million Position in Mednax, Inc (MD)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/16/nationwide-fund-advisors-has-28-25-million-position-in-mednax-inc-md.html.

Shares of Mednax, Inc (NYSE:MD) traded down 0.33% during midday trading on Friday, reaching $42.90. The company’s stock had a trading volume of 2,071,455 shares. The stock’s 50-day moving average is $43.51 and its 200 day moving average is $57.01. The stock has a market capitalization of $3.95 billion, a P/E ratio of 13.66 and a beta of 0.40. Mednax, Inc has a 12 month low of $41.20 and a 12 month high of $72.13.

Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843.00 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the previous year, the firm earned $1.03 EPS. The firm’s revenue was up 9.2% compared to the same quarter last year. On average, analysts expect that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.

Mednax Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.